| Zacks Company Profile for CSL Limited Sponsored ADR (CSLLY : OTC) |
|
|
| |
| • Company Description |
| CSL Ltd. is a biopharmaceutical company. It engages in researches, develops, manufactures and markets vaccines and plasma protein biotherapies to treat and prevent human medical conditions. The company's operating segments consists of CSL Behring and bioCSL. CSL Behring segment provides plasma-derived and recombinant products, and operates plasma collection networks through CSL Plasma. bioCSL segment manufactures, sells and distributes vaccines, antivenoms and other pharmaceutical products primarily in Australia and New Zealand; as well as also manufactures and markets in vitro diagnostic products through Immunohaematology. It operates primarily in Germany, Switzerland and the United States. CSL Ltd. is headquartered in Parkville, Australia.
Number of Employees: 29,904 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $24.34 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 605,316 shares |
| Shares Outstanding: 1,941.28 (millions) |
| Market Capitalization: $47,250.65 (millions) |
| Beta: 0.80 |
| 52 Week High: $44.86 |
| 52 Week Low: $22.83 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-6.58% |
0.90% |
| 12 Week |
-15.35% |
-8.85% |
| Year To Date |
-15.49% |
-9.16% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Paul McKenzie - Chief Executive Officer and Director
Brian McNamee - Chairman and Director
Mary Oates - Chief Operating Officer
Joy Linton - Chief Financial Officer
Greg Boss - Executive Vice President; Legal and General Counse
|
|
Peer Information
CSL Limited Sponsored ADR (CORR.)
CSL Limited Sponsored ADR (RSPI)
CSL Limited Sponsored ADR (CGXP)
CSL Limited Sponsored ADR (BGEN)
CSL Limited Sponsored ADR (GTBP)
CSL Limited Sponsored ADR (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 12637N204
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: June
Last Reported Quarter: -
Next Expected EPS Date: -
|
|
Share - Related Items
Shares Outstanding: 1,941.28
Most Recent Split Date: 3.00 (2.00:1)
Beta: 0.80
Market Capitalization: $47,250.65 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 2.47% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.60 |
| Current Fiscal Year EPS Consensus Estimate: $3.48 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 1.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: 8.83% |
Last Dividend Paid: 03/11/2026 - $0.30 |
| Next EPS Report Date: - |
|
|
|
| |
